Komori
Stella Pharma (4888) · InitiativeAdvanced

Stable Supply Through Dual-Sourcing of Raw Materials and Inventory Management

First written in FY2021. 12 of 16 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-10-19.

16entries
6years
11from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021 – FY20252021: 120212022: 120222023: 020232024: 020242025: 220252026: 122026
Same theme, other companies
Stable procurement of raw materials and components through multiple sourcingA theme 23 companies write about · 0 as a headwind · 23 as a tailwind

The whole theme swung hardest in 2023: 1 of 8 companies on the "Worse" side.

7 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 23 companies compared. The sentences above are computed from all 23.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Regarding progress in the production transfer, pilot production at the pilot plant was completed by the end of December 2025 as originally planned.」

    Regarding the rebuilding of the stable supply system following the change in contract manufacturer, prototype production at the pilot plant was completed at the end of December 2025, advancing preparations toward the start of full-scale manufacturing during the fiscal year ending March 2027.
  2. FY2026-H1AdvancedAnnual report

    「Because the company commissioned to manufacture our product 「ステボロニン®」 entered bankruptcy proceedings on 5 September 2025, we suspended transactions with it. To promptly rebuild a stable product supply system, we have been holding discussions with a domestic operating company selected as our new contract manufacturer and, as stated in the notice entitled 「Notice Regarding the Execution of an Agreement with a New Contract Manufacturing Partner」 announced on 2 October 2025, entered into a development and contract manufacturing agreement with that company to establish a manufacturing system aimed at ensuring a stable long-term supply.」

    Following the bankruptcy of the contract manufacturer, entered into a development and contract manufacturing agreement with a new domestic contract manufacturer and advanced to the stage of transferring production and rebuilding the stable supply system.
  3. FY2025RestatedAnnual report

    「Because alternative procurement is particularly difficult for certain raw materials, we secure sufficient inventory, in forms such as intermediates that can be stored for long periods, to meet sales for a considerable period and maintain stable supply even in the event of a disaster. We will also continue to pursue second sourcing of raw materials.」

    Continues to secure sufficient inventory of difficult-to-source raw materials, in the form of long-term storable intermediates, and pursue second sourcing.
  4. FY2022RestatedAnnual report

    「While maintaining and improving stable supply through manufacturing and quality control based on stringent standards, rigorous demand forecasting and the maintenance of appropriate inventory levels, we will, because alternative raw materials are currently unavailable, continue to pursue second sourcing of raw materials and secure sufficient inventory to meet sales for a considerable period so that stable supply can be maintained in the event of disasters and other contingencies.」

    Continues its policy of stable supply through quality control, demand forecasting, appropriate inventory levels and second sourcing of raw materials.
  5. FY2021First statedAnnual report

    「While maintaining and improving stable supply through manufacturing and quality control based on stringent standards, rigorous demand forecasting and the maintenance of appropriate inventory levels, we will, because alternative raw materials are currently unavailable, pursue second sourcing of raw materials and secure sufficient inventory to meet sales for a considerable period, based on our BCP (business continuity plan) formulated to maintain stable supply in the event of disasters and other contingencies.」

    Identifies quality control, demand forecasting, appropriate inventory levels and second sourcing as specific measures for stable supply.
Moved together

"Strategy to expand the domestic indications for Steboronin" moved the same way as this thread, in the same document, in 7 of its 16 moves.

777666★123456
  1. ★This thread
  2. 1Strategy to expand the domestic indications for Steboronin7×
  3. 2Preparation for an application to expand the indication for recurrent malignant glioma and make partial changes7×
  4. 3R&D into Deep-Seated Tumor Treatment Using BNCT7×
  5. 4Phase II clinical trial for recurrent high-grade meningioma6×
  6. 5Global Expansion Through U.S. and European Regulatory Approvals and Partnerships6×
  7. 6Phase I clinical trial for malignant melanoma and angiosarcoma6×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Stella Pharma yet. It last moved in the Share Issuance and Disposal of 2026-10-19: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Stable Supply Through Dual-Sourcing of Raw Materials and Inventory Management | STELLA PHARMA CORPORATION (4888) | Komori